阜外医院体外膜肺氧合支持治疗的临床研究
|
摘要
研究目的
回顾性总结阜外医院107例心肺功能衰竭患者应用体外膜肺氧合(ECMO)支持治疗的临床经验,分析早期及中长期预后及其影响因素。
研究方法
2004年12月至2008年12月,对本院107例终末期心脏病和心脏术后需心肺支持的患者行ECMO支持治疗,ECMO系统的氧合器及离心泵内膜均采用全肝素涂抹技术,婴幼儿采用右心房—升主动脉插管,成人应用右心房-股动脉插管或股动-静脉插管,辅助期间流量范围在40～220 ml/(kg·min)。
研究结果
107例患者,男71例(66.4%),女36例(33.6);年龄出生5天～76岁,平均(28.86±25.20)岁;体重3.2～100 kg,平均(43.49±29.04)kg。97例(90.7%)心脏术后安装ECMO;10(9.3%)例内科心肺复苏后安装ECMO(终末期心肌病6例,冠心病2例,主动脉瓣置换术后心衰1例,暴发型心肌炎1例)。辅助时间为12～504h,平均(128.86±86.64)h。康复出院62例(57.9%,62/107),ECMO平均时间(118.08±69.58)h;45例患者院内死亡(42.1%,45/107),ECMO平均时间(143.71±104.79)h;其中6例为顺利撤除ECMO装置后死亡。总撤机率63.6%。由于脱离CPB困难直接转为ECMO辅助的患者及因肺动脉高压需要ECMO支持治疗的患者出院率较高。出院患者体重明显大于死亡患者(P=0.001),ECMO前平均动脉压(MAP)显著高于死亡组(P=0.038);死亡患者ECMO辅助时间显著延长(P=0.009),ECMO前血乳酸水平显著增高(P=0.005)。出血、肾功能衰竭、感染、氧合器渗漏等是ECMO重要并发症。与死亡率显著性相关的并发症为出血、肾衰、溶血、感染、远端肢体缺血坏死、MSOF、DIC、氧合器渗漏及更换氧合器。62例出院患者电话随访至2009年3月31日,其中6例由于电话号码为空号缺失,随访率为90.3%;其余56例患者中7例死亡,平均存活时间97.0±80.0d,余49例患者存活,占全部出院患者的79.0%。存活患者中有5例股动脉插管侧腿部感不适,轻微影响活动;1例冠脉搭桥患者出院14个月后因心绞痛再次入院5d;1例冠脉搭桥患者出院后因胸闷再次入当地医院治疗。所有存活小儿患者生长发育正常,正常上学。
结论
ECMO支持是一种有效的循环呼吸衰竭辅助支持治疗方法,尽早对心肺衰竭患者使用ECMO支持治疗,避免重要脏器不可逆损伤,对提高治疗效果有积极的帮助。ECMO期间及术后并发症直接威胁患者的生命,如何进一步提高ECMO辅助效果,减少和避免并发症,需要ECMO工作者更加深入研究,同时提高对严重并发症的治疗效果也是提高ECMO临床效果的有力保障。
研究目的
回顾性总结分析阜外医院45例小儿体外膜肺氧合(extracorporeal membraneoxygenation,ECMO)支持治疗的临床结果和经验。
研究方法
2004年12月至2008年12月共实施小儿ECMO病例45例,所有患儿均行静脉-动脉ECMO辅助,激活凝血时间维持140～180秒,肝素用量5～20U/(kg·h)。辅助期间平均流量在40～220ml/(kg·min)。
研究结果
45例心脏术后小儿患者,男25例,女20例。平均年龄2.9±4.3岁(5天～16岁);平均体重13.0±12.5 Kg(3.2～50 Kg);平均ECMO辅助时间152.04±93.14h(16～504 h)。22例患者成功撤离ECMO,撤机率为48.9%;20例患者出院,出院率为44.4%。2例成功撤离ECMO后死亡,其中1例存活5d后死于MSOF,1例存活9d后死于感染性休克。23例不能撤离ECMO,终止治疗,院内死亡。出院患儿ECMO支持时间为16～268h,平均(64.21±14.36)h,死亡患儿ECMO支持时间为25～504h,平均(109.88±21.98)h,存在统计学差异(P=0.05);出院组与死亡组的平均年龄、体重有显著差异(P=0.000);并发症中肾功能不全、感染及氧合器渗漏的患儿死亡率显著上升;多因素回归分析结果显示肾功能不全与死亡率显著相关。20例出院患儿电话随访至2009年3月31日,2例由于电话号码为空号缺失,随访率为90.0%;余18例患儿中,1例出院后1天死亡,1例出院后57天死亡;余16例患儿存活至今,生长发育正常,正常上学。
结论
ECMO支持治疗在小儿复杂先天性心脏病术后循环呼吸衰竭的治疗中是一种有效的机械辅助方法。手术畸形矫正满意,尽早对心肺衰竭的患儿使用ECMO支持治疗,避免重要脏器的不可逆损伤是ECMO成功的关键。
研究目的
总结17例终末期心脏病患者应用体外膜肺氧合(ECMO)支持治疗的临床经验。
研究方法
自2005年7月至2008年12月,对17例终末期心脏病患者行ECMO支持治疗,男13例,女4例,年龄15～67岁,平均(40.53±16.73)岁;体重42.5～100 Kg,平均(63.94±16.83)kg。其中终末期心肌病13例,冠心病2例,瓣膜置换术后行心脏移植术2例。所有患者在ECMO支持治疗前都伴有难以控制的心源性休克和/或急性呼吸衰竭。所有患者均采用股动-静脉插管行ECMO支持治疗。ECMO期间镇静或清醒,维持血流动力学和血气指标稳定。
研究结果
ECMO辅助支持时间20～416h,平均(125.5±107.8)h。16例患者顺利脱离ECMO,成功撤机率94.1%;其中15例出院(2例为ECMO支持治疗过渡至心脏移植,11例为移植术后辅助,2例内科患者),总出院率88.2%。15例出院患者电话随访至2009年3月31日,无缺失病例,随访率为100%。1例内科患者2年前死亡,具体原因不详,存活时间为575天;1例移植患者出院不久死亡,存活时间为3天;其余患者存活,占全部出院患者的86.7%(13/15),2例患者出现股动脉插管侧腿部感不适,轻微影响活动。1例成功撤离ECMO5d后,由于感染死亡;1例患者不能脱机,家属放弃治疗死亡。
结论
ECMO可对终末期心脏病合并急性心肺功能衰竭患者提供有效的支持治疗,为心脏移植或心功能的恢复赢得时间,延长部分高危患者的生命。
研究目的
体外膜肺氧合(ECMO)期间的并发症可分为机械系统并发症和患者机体并发症,机械系统并发症包括氧合器功能衰竭、循环管道血栓以及驱动泵和热交换器功能异常;患者机体并发症包括出血、神经系统并发症、器官功能衰竭和感染等。本研究回顾性分析总结阜外心血管病医院107例应用ECMO支持治疗患者的并发症发生情况,探讨ECMO并发症的发生和防治,降低并发症的发生,提高ECMO救治水平。
研究方法
阜外医院2004年12月至2008年12月共107例患者行ECMO支持治疗,回顾性分析总结其临床资料,并发症发生情况、原因、防治及并发症对ECMO结果的影响。全套ECMO系统,包括插管、循环管道、膜肺及离心泵头均为肝素涂抹。所有患者均采用静脉到动脉的ECMO辅助方式(V-A ECMO)。激活凝血时间(ACT)维持于120～180秒,肝素用量为5～20U/(Kg·h)。流量根据患者病情及监测指标来调整,辅助期间流量范围在40～220 ml/(kg·min)。
研究结果
107例接受ECMO支持治疗的患者,68例(63.6%,68/107)顺利撤离ECMO装置,其中康复出院62例(89.9%,62/69);6例患者撤机后院内死亡。45例患者因多种原因不能脱机或放弃治疗。总出院率为57.9%。83例患者发生了各类并发症,24例患者未发生并发症,并发症发生率为77.6%。机械并发症主要有氧合器渗漏、氧合器及管路血栓等,发病率分别为30.8%及20.6%。患者机体并发症主要包括出血、肾功能不全、感染、神经系统并发症、多器官功能衰竭(MSOF)、肢体缺血坏死等,发病率分别为32.7%、28.3%、11.2%、7.48%、5.61%及8.41%。与死亡率显著性相关的并发症有:出血、肾衰、溶血、感染、远端肢体缺血坏死、MSOF、DIC、氧合器渗漏。
结论
ECMO并发症较多,危害较大。ECMO支持时间越长,其发生并发症的危险性就越大,出血是ECMO最主要的机体并发症,氧合器渗漏是最主要的机械并发症。ECMO开始后,应积极监测及预防并发症的发生,一旦出现并发症,应积极治疗以挽救患者生命。
Objective
Retrospectively summarized and analyzed the early outcome and long-term outcome of 107 consecutive extracorporeal membrane oxygenation(ECMO) cases performed in Fuwai Hospital and determine specific predictors of survival.
Methods
Reviewed the clinical protocols of 107 ECMO from Dec.2004 to Dec.2008 in Fuwai Hospital.The inter-surface of the ECMO equipment system was completely coated by heparin-coating technique.All patients were applied veno-artery ECMO and activated clotting time(ACT) was maintained between 120～180 sec and heparin usage dose was 5～20U/(Kg·h).Mean blood flow was 40～220ml/(Kg·min) during ECMO assistant period.
Results
We support 107 patients(age range 5days～76 years,median age 28.86±25.20 years;weight range 3.2～100 kg,medianweight 43.49±29.04 kg) with extracorporeal membrane oxygenation.The shortest ECMO time was 12 hrs and the longest was 504 hrs with mean time was 128.86±86.64 hrs.68 patients(63.6%) weaned off successfully from ECMO.62 of them were discharged and 6 died of post-operative complications.45 patients could not weaned off from ECMO.Total survival discharge rate was 57.9%.The survival discharge rate is significantly higher in patients whose ECMO indication is failure to withdraw from cardiopulmonary bypass and pulmonary hypertension.Lactic acid concentration of artery blood before ECMO in survived patients was significantly lower than that of dead patients(P =0.005).MAP before ECMO in survived patients was significantly higher than that of dead patients(P=0.038).Weights and ECMO duration between the survival and the dead also had statistic difference(P=0.001 and 0.009 separately).Bleeding,renal failure,hemolysis,infection,lower limb ischemia,MSOF,DIC,Oxygenator plasma leakage are the complications significantly related to the dead.The follow up study that used telephone interviews found that 6 case missing and 7 patients died while other 49 patients alive after clischarged.
Conclusions
ECMO is an effective mechanical assistant therapy method for cardiac and pulmonary failure after cardiac surgery.Earlier usage of ECMO for heart lung failure patient and avoiding the main organs from un-recovery trauma are still the key point of success of ECMO.
Objective
To retrospectively summarize and analyze the files of consecutive 45 pediatric ECMO performed in Fuwai Hospital.
Methods
We reviewed the clinical protocols of 45 pediatric ECMO after cardiac surgery from Dec.2004 to Dec.2008 in our hospital.All patients applied veno-artery ECMO and active clotting time(ACT)maintained between 140～180sec and heparin usage dose was 5～20 U /(kg·h).Mean blood flow was 40～220 ml /(kg·min)during ECMO assistant period.
Results
The shortest ECMO time was 16h and longest 504h and mean time 152h.ECMO were weaned off successfully in 22 patients and 20 of them were survival to discharged and 2 of them were died of persistent cardiopulmonary failure or post-operation complications.23 patients could not been weaned off ECMO.Total survival discharge rate was 44.4%(20/45)in this cohort study.Mean age and weight in survived patients was significantly higher than that of dead patients.ECMO duration and complications(renal failure、infection、oxygenator plasma leakage) between the survivors and the nonsurvivors also had statistic difference.The follow up study that used telephone interviews found that 2 case missing and 2 patients died while other 16 patients alive after discharged.
Conclusions
ECMO is an effective mechanical assistant therapy for cardiac and pulmonary failure patients after cardiac surgery with pediatric complicated congenital heart disease.Perfect correction of abnormality and earlier usage of ECMO for cardiac and respiratory failure patients and avoiding the main organs from irreversible injury are still the key of success of ECMO.
Objective
To summarize the clinical experience of extracorporeal membrane oxygenation(ECMO) support for end-stage cardiopathy(ESC) in our hospital.
Methods
From Jul.2005 to Dec.2008,ECMO support for ESC was performed in 17 patients(13 with end-stage cardiomyopathy,2 with coronary heart disease, 2 with post valve replacement,male 13,female 4,15～67 years old,weight 42.5～100kg).All patients developed refractory cardiogenic shock and/or acute pulmonary dysfunction.The ECMO cannulation was performed through femoral vessels.The patients were sedatived or conscious during ECMO. Hemodynamic and respiratory parameters were made stably.
Results
Mean duration of ECMO was 125.5 hours(20～416hours).16 patients were successfully weaned from ECMO,15 patients of which survived.1 patient could not wean form ECMO.The follow up study that used telephone interviews found that 2 patients died while other 13 patients alive after discharged.
Conclusion
ECMO is an effective technique of treatment on ESC patients with refractory cardiogenic shock and acute pulmonary dysfunction.It can prolong some ESC Datients' lives.
Objective
The complications associated with extracorporeal membrane oxygenation (ECMO)can be classified into mechanical and patient—medical complications.Mechanical complications include oxygenator failure,tubing clots,pump and heat exchanger malfunction.Patient—related medical problems are bleeding,neurological complications,organ failure and infection.The objective of this study was to retrospectively investigate and analyze the data of 107 consecutive ECMO cases performed in Fuwai Hospital.
Methods
The author reviewed clinical records of the ECMO patients in Fuwai Hospital from Dec.2004 to Dec.2008.A total of 107 patients with the ECMO supported in our hospital were studied for the incidence of complications.The inter-surface of the ECMO equipment system was completely coated by heparin-coating technique.All patients were applied veno-artery ECMO and activated clotting time(ACT) was maintained between 120～180 sec and heparin usage dose was 5～20U/(Kg·h).Mean blood flow was 40～220ml/(Kg·min) during ECMO assistant period.
Results
We support 107 patients(age range 5days～76 years,median age 28.86±25.20 years;weight range 3.2～100 kg,median weight 43.49±29.04 kg) with extracorporeal membrane oxygenation.68 patients(63.6%) weaned off successfully from ECMO.62 of them were discharged and 6 died of post-operative complications.45 patients could not weaned off from ECMO. Total survival discharge rate was 57.9%.They suffered the complications, such as bleeding,infection,renal failure,neurological complications,MSOF, limb ischemia and oxygenator plasma leakage with the incidence of 32.7%, 11.2%,28.3%,7.48%,5.61%,8.41%and 30.8%respectively.Bleeding, renal failure,hemolysis,infection,limb ischemia,MSOF,DIC and oxygenator plasma leakage are significantly related to nonsurvival rate.
Conclusions
Generally,the risk of complications increases with the duration of time on ECMO support.Bleeding and oxygenator plasma leakage are the most important complications of ECMO.During the ECMO treatment,it is also important of prevent from the complications.Once they occur,active therapies must be carried out to save the patients lives.
回顾性总结阜外医院107例心肺功能衰竭患者应用体外膜肺氧合(ECMO)支持治疗的临床经验,分析早期及中长期预后及其影响因素。
研究方法
2004年12月至2008年12月,对本院107例终末期心脏病和心脏术后需心肺支持的患者行ECMO支持治疗,ECMO系统的氧合器及离心泵内膜均采用全肝素涂抹技术,婴幼儿采用右心房—升主动脉插管,成人应用右心房-股动脉插管或股动-静脉插管,辅助期间流量范围在40～220 ml/(kg·min)。
研究结果
107例患者,男71例(66.4%),女36例(33.6);年龄出生5天～76岁,平均(28.86±25.20)岁;体重3.2～100 kg,平均(43.49±29.04)kg。97例(90.7%)心脏术后安装ECMO;10(9.3%)例内科心肺复苏后安装ECMO(终末期心肌病6例,冠心病2例,主动脉瓣置换术后心衰1例,暴发型心肌炎1例)。辅助时间为12～504h,平均(128.86±86.64)h。康复出院62例(57.9%,62/107),ECMO平均时间(118.08±69.58)h;45例患者院内死亡(42.1%,45/107),ECMO平均时间(143.71±104.79)h;其中6例为顺利撤除ECMO装置后死亡。总撤机率63.6%。由于脱离CPB困难直接转为ECMO辅助的患者及因肺动脉高压需要ECMO支持治疗的患者出院率较高。出院患者体重明显大于死亡患者(P=0.001),ECMO前平均动脉压(MAP)显著高于死亡组(P=0.038);死亡患者ECMO辅助时间显著延长(P=0.009),ECMO前血乳酸水平显著增高(P=0.005)。出血、肾功能衰竭、感染、氧合器渗漏等是ECMO重要并发症。与死亡率显著性相关的并发症为出血、肾衰、溶血、感染、远端肢体缺血坏死、MSOF、DIC、氧合器渗漏及更换氧合器。62例出院患者电话随访至2009年3月31日,其中6例由于电话号码为空号缺失,随访率为90.3%;其余56例患者中7例死亡,平均存活时间97.0±80.0d,余49例患者存活,占全部出院患者的79.0%。存活患者中有5例股动脉插管侧腿部感不适,轻微影响活动;1例冠脉搭桥患者出院14个月后因心绞痛再次入院5d;1例冠脉搭桥患者出院后因胸闷再次入当地医院治疗。所有存活小儿患者生长发育正常,正常上学。
结论
ECMO支持是一种有效的循环呼吸衰竭辅助支持治疗方法,尽早对心肺衰竭患者使用ECMO支持治疗,避免重要脏器不可逆损伤,对提高治疗效果有积极的帮助。ECMO期间及术后并发症直接威胁患者的生命,如何进一步提高ECMO辅助效果,减少和避免并发症,需要ECMO工作者更加深入研究,同时提高对严重并发症的治疗效果也是提高ECMO临床效果的有力保障。
研究目的
回顾性总结分析阜外医院45例小儿体外膜肺氧合(extracorporeal membraneoxygenation,ECMO)支持治疗的临床结果和经验。
研究方法
2004年12月至2008年12月共实施小儿ECMO病例45例,所有患儿均行静脉-动脉ECMO辅助,激活凝血时间维持140～180秒,肝素用量5～20U/(kg·h)。辅助期间平均流量在40～220ml/(kg·min)。
研究结果
45例心脏术后小儿患者,男25例,女20例。平均年龄2.9±4.3岁(5天～16岁);平均体重13.0±12.5 Kg(3.2～50 Kg);平均ECMO辅助时间152.04±93.14h(16～504 h)。22例患者成功撤离ECMO,撤机率为48.9%;20例患者出院,出院率为44.4%。2例成功撤离ECMO后死亡,其中1例存活5d后死于MSOF,1例存活9d后死于感染性休克。23例不能撤离ECMO,终止治疗,院内死亡。出院患儿ECMO支持时间为16～268h,平均(64.21±14.36)h,死亡患儿ECMO支持时间为25～504h,平均(109.88±21.98)h,存在统计学差异(P=0.05);出院组与死亡组的平均年龄、体重有显著差异(P=0.000);并发症中肾功能不全、感染及氧合器渗漏的患儿死亡率显著上升;多因素回归分析结果显示肾功能不全与死亡率显著相关。20例出院患儿电话随访至2009年3月31日,2例由于电话号码为空号缺失,随访率为90.0%;余18例患儿中,1例出院后1天死亡,1例出院后57天死亡;余16例患儿存活至今,生长发育正常,正常上学。
结论
ECMO支持治疗在小儿复杂先天性心脏病术后循环呼吸衰竭的治疗中是一种有效的机械辅助方法。手术畸形矫正满意,尽早对心肺衰竭的患儿使用ECMO支持治疗,避免重要脏器的不可逆损伤是ECMO成功的关键。
研究目的
总结17例终末期心脏病患者应用体外膜肺氧合(ECMO)支持治疗的临床经验。
研究方法
自2005年7月至2008年12月,对17例终末期心脏病患者行ECMO支持治疗,男13例,女4例,年龄15～67岁,平均(40.53±16.73)岁;体重42.5～100 Kg,平均(63.94±16.83)kg。其中终末期心肌病13例,冠心病2例,瓣膜置换术后行心脏移植术2例。所有患者在ECMO支持治疗前都伴有难以控制的心源性休克和/或急性呼吸衰竭。所有患者均采用股动-静脉插管行ECMO支持治疗。ECMO期间镇静或清醒,维持血流动力学和血气指标稳定。
研究结果
ECMO辅助支持时间20～416h,平均(125.5±107.8)h。16例患者顺利脱离ECMO,成功撤机率94.1%;其中15例出院(2例为ECMO支持治疗过渡至心脏移植,11例为移植术后辅助,2例内科患者),总出院率88.2%。15例出院患者电话随访至2009年3月31日,无缺失病例,随访率为100%。1例内科患者2年前死亡,具体原因不详,存活时间为575天;1例移植患者出院不久死亡,存活时间为3天;其余患者存活,占全部出院患者的86.7%(13/15),2例患者出现股动脉插管侧腿部感不适,轻微影响活动。1例成功撤离ECMO5d后,由于感染死亡;1例患者不能脱机,家属放弃治疗死亡。
结论
ECMO可对终末期心脏病合并急性心肺功能衰竭患者提供有效的支持治疗,为心脏移植或心功能的恢复赢得时间,延长部分高危患者的生命。
研究目的
体外膜肺氧合(ECMO)期间的并发症可分为机械系统并发症和患者机体并发症,机械系统并发症包括氧合器功能衰竭、循环管道血栓以及驱动泵和热交换器功能异常;患者机体并发症包括出血、神经系统并发症、器官功能衰竭和感染等。本研究回顾性分析总结阜外心血管病医院107例应用ECMO支持治疗患者的并发症发生情况,探讨ECMO并发症的发生和防治,降低并发症的发生,提高ECMO救治水平。
研究方法
阜外医院2004年12月至2008年12月共107例患者行ECMO支持治疗,回顾性分析总结其临床资料,并发症发生情况、原因、防治及并发症对ECMO结果的影响。全套ECMO系统,包括插管、循环管道、膜肺及离心泵头均为肝素涂抹。所有患者均采用静脉到动脉的ECMO辅助方式(V-A ECMO)。激活凝血时间(ACT)维持于120～180秒,肝素用量为5～20U/(Kg·h)。流量根据患者病情及监测指标来调整,辅助期间流量范围在40～220 ml/(kg·min)。
研究结果
107例接受ECMO支持治疗的患者,68例(63.6%,68/107)顺利撤离ECMO装置,其中康复出院62例(89.9%,62/69);6例患者撤机后院内死亡。45例患者因多种原因不能脱机或放弃治疗。总出院率为57.9%。83例患者发生了各类并发症,24例患者未发生并发症,并发症发生率为77.6%。机械并发症主要有氧合器渗漏、氧合器及管路血栓等,发病率分别为30.8%及20.6%。患者机体并发症主要包括出血、肾功能不全、感染、神经系统并发症、多器官功能衰竭(MSOF)、肢体缺血坏死等,发病率分别为32.7%、28.3%、11.2%、7.48%、5.61%及8.41%。与死亡率显著性相关的并发症有:出血、肾衰、溶血、感染、远端肢体缺血坏死、MSOF、DIC、氧合器渗漏。
结论
ECMO并发症较多,危害较大。ECMO支持时间越长,其发生并发症的危险性就越大,出血是ECMO最主要的机体并发症,氧合器渗漏是最主要的机械并发症。ECMO开始后,应积极监测及预防并发症的发生,一旦出现并发症,应积极治疗以挽救患者生命。
Objective
Retrospectively summarized and analyzed the early outcome and long-term outcome of 107 consecutive extracorporeal membrane oxygenation(ECMO) cases performed in Fuwai Hospital and determine specific predictors of survival.
Methods
Reviewed the clinical protocols of 107 ECMO from Dec.2004 to Dec.2008 in Fuwai Hospital.The inter-surface of the ECMO equipment system was completely coated by heparin-coating technique.All patients were applied veno-artery ECMO and activated clotting time(ACT) was maintained between 120～180 sec and heparin usage dose was 5～20U/(Kg·h).Mean blood flow was 40～220ml/(Kg·min) during ECMO assistant period.
Results
We support 107 patients(age range 5days～76 years,median age 28.86±25.20 years;weight range 3.2～100 kg,medianweight 43.49±29.04 kg) with extracorporeal membrane oxygenation.The shortest ECMO time was 12 hrs and the longest was 504 hrs with mean time was 128.86±86.64 hrs.68 patients(63.6%) weaned off successfully from ECMO.62 of them were discharged and 6 died of post-operative complications.45 patients could not weaned off from ECMO.Total survival discharge rate was 57.9%.The survival discharge rate is significantly higher in patients whose ECMO indication is failure to withdraw from cardiopulmonary bypass and pulmonary hypertension.Lactic acid concentration of artery blood before ECMO in survived patients was significantly lower than that of dead patients(P =0.005).MAP before ECMO in survived patients was significantly higher than that of dead patients(P=0.038).Weights and ECMO duration between the survival and the dead also had statistic difference(P=0.001 and 0.009 separately).Bleeding,renal failure,hemolysis,infection,lower limb ischemia,MSOF,DIC,Oxygenator plasma leakage are the complications significantly related to the dead.The follow up study that used telephone interviews found that 6 case missing and 7 patients died while other 49 patients alive after clischarged.
Conclusions
ECMO is an effective mechanical assistant therapy method for cardiac and pulmonary failure after cardiac surgery.Earlier usage of ECMO for heart lung failure patient and avoiding the main organs from un-recovery trauma are still the key point of success of ECMO.
Objective
To retrospectively summarize and analyze the files of consecutive 45 pediatric ECMO performed in Fuwai Hospital.
Methods
We reviewed the clinical protocols of 45 pediatric ECMO after cardiac surgery from Dec.2004 to Dec.2008 in our hospital.All patients applied veno-artery ECMO and active clotting time(ACT)maintained between 140～180sec and heparin usage dose was 5～20 U /(kg·h).Mean blood flow was 40～220 ml /(kg·min)during ECMO assistant period.
Results
The shortest ECMO time was 16h and longest 504h and mean time 152h.ECMO were weaned off successfully in 22 patients and 20 of them were survival to discharged and 2 of them were died of persistent cardiopulmonary failure or post-operation complications.23 patients could not been weaned off ECMO.Total survival discharge rate was 44.4%(20/45)in this cohort study.Mean age and weight in survived patients was significantly higher than that of dead patients.ECMO duration and complications(renal failure、infection、oxygenator plasma leakage) between the survivors and the nonsurvivors also had statistic difference.The follow up study that used telephone interviews found that 2 case missing and 2 patients died while other 16 patients alive after discharged.
Conclusions
ECMO is an effective mechanical assistant therapy for cardiac and pulmonary failure patients after cardiac surgery with pediatric complicated congenital heart disease.Perfect correction of abnormality and earlier usage of ECMO for cardiac and respiratory failure patients and avoiding the main organs from irreversible injury are still the key of success of ECMO.
Objective
To summarize the clinical experience of extracorporeal membrane oxygenation(ECMO) support for end-stage cardiopathy(ESC) in our hospital.
Methods
From Jul.2005 to Dec.2008,ECMO support for ESC was performed in 17 patients(13 with end-stage cardiomyopathy,2 with coronary heart disease, 2 with post valve replacement,male 13,female 4,15～67 years old,weight 42.5～100kg).All patients developed refractory cardiogenic shock and/or acute pulmonary dysfunction.The ECMO cannulation was performed through femoral vessels.The patients were sedatived or conscious during ECMO. Hemodynamic and respiratory parameters were made stably.
Results
Mean duration of ECMO was 125.5 hours(20～416hours).16 patients were successfully weaned from ECMO,15 patients of which survived.1 patient could not wean form ECMO.The follow up study that used telephone interviews found that 2 patients died while other 13 patients alive after discharged.
Conclusion
ECMO is an effective technique of treatment on ESC patients with refractory cardiogenic shock and acute pulmonary dysfunction.It can prolong some ESC Datients' lives.
Objective
The complications associated with extracorporeal membrane oxygenation (ECMO)can be classified into mechanical and patient—medical complications.Mechanical complications include oxygenator failure,tubing clots,pump and heat exchanger malfunction.Patient—related medical problems are bleeding,neurological complications,organ failure and infection.The objective of this study was to retrospectively investigate and analyze the data of 107 consecutive ECMO cases performed in Fuwai Hospital.
Methods
The author reviewed clinical records of the ECMO patients in Fuwai Hospital from Dec.2004 to Dec.2008.A total of 107 patients with the ECMO supported in our hospital were studied for the incidence of complications.The inter-surface of the ECMO equipment system was completely coated by heparin-coating technique.All patients were applied veno-artery ECMO and activated clotting time(ACT) was maintained between 120～180 sec and heparin usage dose was 5～20U/(Kg·h).Mean blood flow was 40～220ml/(Kg·min) during ECMO assistant period.
Results
We support 107 patients(age range 5days～76 years,median age 28.86±25.20 years;weight range 3.2～100 kg,median weight 43.49±29.04 kg) with extracorporeal membrane oxygenation.68 patients(63.6%) weaned off successfully from ECMO.62 of them were discharged and 6 died of post-operative complications.45 patients could not weaned off from ECMO. Total survival discharge rate was 57.9%.They suffered the complications, such as bleeding,infection,renal failure,neurological complications,MSOF, limb ischemia and oxygenator plasma leakage with the incidence of 32.7%, 11.2%,28.3%,7.48%,5.61%,8.41%and 30.8%respectively.Bleeding, renal failure,hemolysis,infection,limb ischemia,MSOF,DIC and oxygenator plasma leakage are significantly related to nonsurvival rate.
Conclusions
Generally,the risk of complications increases with the duration of time on ECMO support.Bleeding and oxygenator plasma leakage are the most important complications of ECMO.During the ECMO treatment,it is also important of prevent from the complications.Once they occur,active therapies must be carried out to save the patients lives.
引文
1.Brown KL,Goldman AP.Neonatal extra-corporeal life support:indications and limitations[J].Early Hum Dev,2008,84(3):143-148.
2.Schuerer DJ,Kolovos NS,Boyd KV,et al.Extracorporeal membrane oxygenation:current clinical practice,coding,and reimbursement[J].Chest,2008,134(1):179-184.
3.Shu-Chien Huang,En-Ting Wu,Yih-Shang Chen,et al.Experience with extracorporeal life support in pediatric patients after cardiac surgery[J].ASAIO J,2005,51(5):517-521.
4.Baslaim G,Bashore J,Al-Malki F,et al.Can the outcome of pediatric extracorporeal membrane oxygenation after cardiac surgery be predicted[J]?Ann Thorac Cardiovasc Surg,2006,12(1):21-27.
5.Ghez O,Feier H,Ughetto F,et al.Postoperative extracorporeal life support in pediatric cardiac surgery:recent results[J].ASAIO J,2005,51(5):513-516.
6.Goldman AP,Cassidy J,de Leval M,et al.The waiting game:bridging to pediatric heart transplantation[J].Lancet,2003,362(9400):1967-1970.
7.Ducan BW,Bhon DJ,Alz AM,et al.Mechamical circulatory support for the treatment of children with acute fulminant myocarditis[J].J Thorac Cardiovac Surg,2001,122(3):440-448.
8.Dietl CA,Wernly JA,Pett SB,et al.Extracorporeal membrane oxygenation support improves survival of patients with severe Hantavirus cardiopulmonary syndrome[J].J Thorac Cardiovasc Surg,2008,135(3):579-584.
9.Shah Salman,Shankar V,Kevin B,et al.Clinical outcomes of 84 children with congenital heart disease managed with extracorporeal membrane oxygenation after cardiac surgery[J].ASAIO J,2005,51(5):504-507.
10.Conrad SA,Rycus PT,Dalton HJ,et al.Extracorporeal Life Support Registry Report 2004[J].ASAIO J,2005,51(1):4-10.
11.Doll N,Kiaii B,Borger M,et al.Five-year results of 219 consecutive patients treated with extracorporeal membrane oxygenation for refractory postoperative cardiogenic shock[J].Ann Thorac Surg,2004,77:151-157.
12.Hoskote A,Bohn D,Gruenwald C,et al.Extracorporeal life support after staged palliation of a functional single ventricle:subsequent morbidity and survival[J].J Thorac Cardiovasc Surg,2006,131(5):1114-1121.
13.Meyns B,Vercaemst L,Vandezande E,et al.Plasma leakage of oxygenators in ECMO depends on the type of oxygenator and on patient variables[J].Int J Artif Organs,2005,28(1):30-34.
14.Eash HJ,Jones HM,Hattler BG,et al.Evaluation of plasma resistant hollow fiber membranes for artificial lungs[J].ASAIO J,2004,50(5):491-497.
15.Cattaneo G,Strauss A,Reul H.et al.Compact intra-and extracorporeal oxygenator developments[J].Perfusion,2004,19(4):251-255.
16.Levi D,Marelli D,Plunkett M,et al.Use of assist devices and ECMO to bridge pediatric patients with cardiomyopathy to transplantation[J].J Heart Lung Transplant,2002,21(7):760-770.
17.Meyns B,Vercaemst L,Vandezande E,et al.Plasma leakage of oxygenators in ECMO depends on the type of oxygenator and on patient variables[J].Int J Artif Organs.2005,28(1):30-34.
18.Agati S,Ciccarello G,Fachile N,et al.DIDECMO:A new polymethylpentene oxygenator for pediatric extracorporeal membrane oxygenation[J].ASAIO J,2006,52(5):509-512.
19.Horton S,Thuys C,Bennet M,et al.Experience with the Jostra Rotaflow and Quadrox D oxygenator for ECMO[J].Perfusion,2004,19(1):17-23.
20.Nishinaka T,Tatsumi E,Taenaka Y,et al.At least thirty-four clays of animal continuous perfusion by a newly developed extracorporeal membrane oxygenation system without systemic anticoagulants[J].Artif Organs,2002,26(6):548-551.
21.Motomura T,Maeda T,Kawahito S,et al.Development of silicone rubber hollow fiber membrane oxygenator for ECMO[J].Artif Organs,2003,27(11):1050-1053.
22.Bakhtiary F,Keller H,Dogan S,et al.Venoarterial extracorporeal membrane oxygenation for treatment of cardiogenic shock:clinical experiences in 45 adult patients[J].J Thorac Cardiovasc Surg,2008,135(2):382-388.
23.Wernovsky G.Current insights regarding neurological and developmental abnormalities in children and young adults with complex congenital cardiac disease[J].Cardiol Young,2006,16(Suppl 1):92-104.
24.Chaturvedi RR,Macrae D,Brown KL,et al.Cardiac ECMO for biventricular hearts after pediatric open heart surgery[J].Heart,2004,90(5):545-551.
25.Mahle WT,Forbess JM,Kirshbom PM,et al.Cost-utility analysis of salvage cardiac extracorporeal membrane oxygenation in children[J].J Thorac Cardiovasc Surg,2005,129(5):1084-1090.
26.Hamrick SE,Gremmels DB,Keet CA,et al.Neurodevelopmental outcome of infants supported with extracorporeal membrane oxygenation after cardiac surgery[J].Pediatrics,2003,111(6 Pt 1):e671-e675.
27.Duncan BW,Ibrahim AE,Hraska V,et al.Use of rapid-deployment extracorporeal membrane oxygenator for the resuscitation of pediatric patients with heart disease after cardiac arrest[J].J Thorac Cardiovasc Surg,1998,116(2):305-311.
28.Morris MC,Wernovsky G,Nadkarni VM.Survival outcomes after extracorporeal cardioplumonary resuscitation instituted during active chest compressions following refractory in-hospital pediatric cardiac arrest[J].Pediatr Crit Care Med,2004,5(5):440-446.
29.Zaritsky A.Extracorporeal cardioplumonary resuscitation:ready for prime time[J]?Pediatr Crit Care Med,2004,5(5):495-496.
1 The January 2007 Extracorporeal Life Support Organization(ELSO) extracorporeal Life Support(ELCS) Registry Report International Summary.Ann Arbor,Michigan,Extracorporeal Life Support Organization,2007.
2 Baffes TG,Fridman JL,Bicoff JP,Whitehill JL:Extracorporeal circulation for support of palliative cardiac surgery in infants[J].Ann Thorac Surg 1970,10(4):354-63.
3 Aharon AS,Drinkwater DC Jr,Churchwell KB,et al.Extracorporeal membrane oxygenation in children after repair of congenital cardiac lesions[J].Ann Thorac Surg,2001,72(6):2095-2101.
4 Duncan BW.Pediatric Cardiac Failure:Management and Use of ECLS.ECMO Extracorporeal Cardiopulmonary Support in Critical Care,3rd edn.Ann Arbor:Extracorporeal Life Support Organization,2005:431-444.
5 Haines NM,Rycus PT,Zwischenberger JB,et al.Extracorporeal Life Support Registry Report 2008:neonatal and pediatric cardiac cases[J].ASAI0 J,2009,55(1):47-52.
6 Thiagarajan RR,Laussen PC.Hospital charges and pediatric ECMO[J].Crit Care Med,2005,33(12):A94-A95.
7 Kolovos NS,Bratton SL,Moler FW,et al.Outcome of pediatric patients treated with extracorporeal life support after cardiac surgery[J].Ann Thorac Surg,2003,76(5):1435-1441.
8 Chaturvedi RR,Macrae D,Brown KL,et al.Cardiac ECMO for biventricular hearts after paediatric open heart surgery[J].Heart,2004,90(5):545-551.
9 Morris MC,Ittenbach RF,Godinez RI et al.Risk factors for mortality in 137 pediatric cardiac intensive care unit patients managed with extracorporeal membrane oxygenation[J].Crit Care Med,2004,32(4):1061-1069.
10 Alsoufi B,Shen I,Karamlou T et al.Extracorporeal life support in neonates,infants,and children after repair of congenital heart disease:modern era results in a single institution[J].Ann Thorac Surg,2005,80(1):15-21.
11 Thourani VH,Kirshbom PM,Kanter KR et al.Venoarterial extracorporeal membrane oxygenation(VA-ECMO) in pediatric cardiac support[J].Ann Thorac Surg,2006,82(1):138-144.
12 Hintz SR,Benitz WE,Colby CE et al.Utilization and outcomes of neonatal cardiac extracorporeal life support:1996-2000[J].Pediatr Crit Care Med,2005,6(1):33-38.
13 Conrad SA,Rycus PT,Dalton H.Extracorporeal Life Support Registry Report 2004[J].ASAI0 J,2005,51(1):4-10.
14 Kocis KC.Pediatric cardiac extracorporeal membrane oxygenation:supporting life or prolonging death[J]?Crit Care Med,2000,28(2):594-595.
15 Fiser SM,Tribble CG,Kaza AK,et al.When to discontinue extracorporeal membrane oxygenation for postcardiotomy support[J].Ann Thorac Surg,2001,71:210-214.
16 Shah SA,Shankar V,Kevin B,etal.Clinical outcomes of 84 children with congenital heart disease managed with extracorporeal membrane oxygenation after cardiac surgery[J].ASAI0 J,2005,51(5):504—507.
17 HetzerR,Stiller B.Technology insight:use of ventricular assist devices in children[J].Nat Clin Pract Cardiovasc Med,2006,3(7):377-386.
18 Charpie JR,Dekeon MK,Goldberg CS,et al.Postoperative hemodynamics after Norwood palliation for hypo plastic left heart syndrome[J].Am J Cardiol,2001,87(2):198—202.
19 Extracorporeal Life Support Organization(ELSO).ELSO Registry report international summary,January 2006.
20 Kulik TJ,Moler FW,Palmisano JM,et al,Outcome-associated factors in pediatric patients treated with extracorporeal membrane oxygenator after cardiac surgery[J].Circulation,1996,94(9 suppl),1163-1168.
21 Ravishankar C,Dominguez TE,Kreutzer J,et al.Extracorporeal membrane oxygenation after stage I reconstruction for hypoplastic left heart syndrome[J].Pediatr Crit Care Med,2006,7(4):319-323.
22 Pizarro C,Davis DA,Healy RM,et al.Is there a role for extracorporeal life support after stage I Norwood[J]?Eur J Cardiothorac Surg,2001,19(3):294-301.
23 Catherine K.Allan MD,Ravi R,et al.Indication for initiation of mechanical circulatory support impacts survival of infants with shunted single-ventricle circulation supported with extracorporeal membrane oxygenation[J].The Journal of Thoracic and Cardiovascular Surgery,2007,133(3):660-667.
24 Huang SC,Wu ET,Chen YS,et al:Experience with extracorporeal life support in pediatric patients after cardiac surgery[J].ASAIO J,2005,51(5):517-521.
25 Baslaim G,Bashore J,Al-Malki F,et al:Can the outcome of pediatric extracorporeal membrane oxygenation after cardiac surgery be predicted[J]?Ann Thorac Cardiovasc Surg,2006,12(1):21-27.
26 Montgomery VL,Strotman JM,Ross MP.Impact of multiple organ system dysfunction and nosocomial infections on survival of children treated with extracorporeal membrane oxygenation after heart surgery[J].Crit Care Med,2000,28(2):526-531.
27 Kanter KR,Pennington G,Weber TR,et al.Extrocorporeal membrane oxygenation for postoperative cardiac support in children[J].J Thorac Cardiovasc Surg,1987,93(1):27-35.
28 Wittenstein B,Ng C,Ravn H,et al.Recombinant factor Ⅶ for severe bleeding during extracorporeal membrane oxygenation following open heart surgery[J].Pediatr Crit Care Med 2005,6:473-76.
29 Meyns B,Vercaemst L,Vandezande E,et al.Plasma leakage of oxygenators in ECMO depends on the type of oxygenator and patient variables[J].Int J Artif Organs,2005,28(1):30-34.
30 Eash HJ,Jones HM,Hattler BG,et al.Evaluation of plasma resistant hollow fiber membranes for artificial lungs[J].ASAIO J,2004,50(5):491-497.
31 Cattaneo G,Strauss A,Reul H,et al.Compact intra-and extracorporeal oxygenator development,;[J].Perfusion,2004,19(4):251-255.
32 Levi D,Marelli D,Plunketu M,et al.Use of assist devices and ECMO to bridge pediatric patients with cardiomyopathy to trans plantation[J].J Heart Lung Transplant,2002,21(7):760-770.
33 Wernovsky G.Current insights regarding neurological and developmental abnormalities in children and young adults with complex congenital cardiac disease[J].Cardiol Young,2006,16(Suppl 1):92-104.
34 Mahle WT,Forbess JM,Kirshbom PM,et al.Cost-utility analysis of salvage cardiac extracorporeal membrane oxygenation in children[J].J Thorac Cardiovasc Surg,2005,129(5):1084-1090.
35 Hamrick SE,Gremmels DB,Keet CA,et al.Neurodevelopmental outcome of infants supported with extracorporeal membrane oxygenation after cardiac surgery[J].Pediatrics,2003,111(6 Pt 1):e671-e675.
1 Taylor IX.Edwards LB.Boucek M M,et al.Registry of the international society for heart and lung transplantation:“twenty—second official adult heart transplant report—2005”[J].J Heart Lung Transplant,2005,24(8):945—982.
2 McMahon AM,van Doom C,Burch M,et al.Improved early outcome for end—stage dilated cardiomyopathy in children[J].J Thorac Cardiovasc Surg,2003,126(6):1781—1787.
3 Undar A,McKenzie ED,MeGarry MC,el al.Outcomes of congenital heart surgery patients after extraeorporeal life support at Texas Childrens Hospital[J].Artif Organs,2004,28(10):963—966.
4 Sachweh JS,TieteAR,Fuchs A,et al.Efficacy of extracorporeal membrane oxygenation in a congenital heart surgery program[J].Clin Res Cardiol,2007,96(4):204—210.
5 Van Doom C,Karimova A,Burch M,et al.Sequential use of extracorporeal membrane oxygenation and the Berlin Heart Left Ventricular Assist Device for 106 day bridge to transplant in a two year—old child[J].ASAI0 J,2005,51(5);668—669.
6 Etz C,Welp H,Rothenburger M,et al.Analysis of platelet function during left ventricular support with the lncor and Exeor system[J].Heart Surg Forum,2004,7(5):E423—427.
7 Hsu RB,Chu SH,Chien CY,et al.HeartMate left ventricular assist device for long term circulatory support[J].J Formos Med ASSOC,2000,99(4):336—340.
8 Goldman AP,Cassidy J,de Leval M,et al.The waiting game:bridging to paediatric heart transplantation[J].Lancet,2003,362(9400):1967—1970.
9 Bartlett RH,Gazzaniga AB,Fong SW,et al.Extracorporeal membrane oxygenator support for cardiopulmonary failure:experience in 28 cases[J].J Thorac Cardiovasc Surg,1977,3(3):375-386.
10 Meliones JN,Custer JR,Snedecor S,et al.Extracorporeal life support for cardiac assist in pediatric patients:review of ELS0 registry data[J].Circulation,1991,84(5 Suppl):III168-172.
11 Dalton HJ,Siewers RD,Fuhrman BP,et al.Extracorporeal membrane oxygenation for cardiac rescue in children with severe myocardial dysfunction[J].Crit Care Med,1993,21(7):1020-1028.
12 Wang SS,Ko wJ,Chen YS,et al.Mechanical bridge with extracorporeal membrane oxygenation and ventricular assist device to heart transplantation[J].Artif Organs,2001,25(8):599—602.
13 Farrar DJ,Hill JD.Recovery of major organ's function in patients awaiting heart transplantation with Thoratec ventricular assist devices[J].J Heart Lunf Transplant,1994,13(6):1123-1132.
14 De Maria R,Minoli L,Parolini M,et al.Prognostic determinants of six-month morbidity and mortality in heart transplant recipients.The Italian Study Group on Infection in Heart Transplantation[J].J Heart Lung Transplant,1996,15(2):124-135.
15 Walley VM,Masters RG,Boone SA,et al.Analysis of deaths after heart transplantation:the University of Ottawa Heart Institute experience[J].J Heart Lung Transplant,1993,12(5):790-801.
16 Bourge RC,Naftel DC,Costanzo-Nordin MR,et al.Pretransplantation risk factors for death after heart transplantation:a multiinstitutional study.The Transplant Cardiologists.Research Database Group[J].J Heart Lung Transplant,1993,12(4):549-562.
17 Ko WJ,Chen YS,Chou NK,et al.Extracorporeal membrane oxygenation rescue after heart transplantation[J].Transplant Proc,2000;32(7):2388-2391.
18 Hoffman TM,Spray TL,Gaynor JW,et al.Survival after acute graft failure in pediatric thoracic organ transplant recipients[J].Pediatr Transplant,2000:4(2):112-117.
19 Kaye MP.The Registry of the International Society for Heart and Lung Transplantation:tenth official report—1993[J].J Heart Lung Transplant,1993,12(4):541—548.
20 Obadia JF,Janier M,Dayoub G,et al.Posttransplant primary heart dysfunction and myocardial stunning[J].J Cardiothorac Vasc Anesth,1997,11(7):880-882.
21 Braunwald E,Kloner RA.The stunned myocardium:prolonged,postischemic ventricular dysfunction[J].Circulation,1982,66(6):1146—1149.
22 Chen JM,Levin HR,Michler RE,et al.Reevaluating the significance of pulmonary hypertension before cardiac transplantation:determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality[J].J Thorac Cardiovasc Surg,1997,114(4):627 -634.
23 Kantrowitz A,Haller JD,Joos H,et al.Transplantation of the heart in an infant and an adult[J].Am J Cardiol,1968,22(6):782-790.
24 Vouhe PR,Tamisier D,Le Bidois J,et al.Pediatric cardiac transplantation for congenital heart defects:surgical considerations and results[J].Ann Thorac Surg,1993,56(6):1239-1247.
25 Heck CF,Shumway SJ,Kaye MP.The registry of the International Society for Heart Transplantation:Sixth official report-1989[J].J Heart Transplant,1989,8(4):271-276.
26 Kanter KR,Tarn VK,Vincent RN,et al.Current results with pediatric heart transplantation[J].Ann Thorac Surg,1999,68(2):527-531.
27 Shaffer KM,Denfield SW,Schowengerdt KO,et al.Cardiac transplantation for pediatric patients with inoperable congenital heart disease[J].Tex Heart Inst J,1998,25(1):57-63.
28 Fullerton DA,Campbell DN,Jones SD,et al.Heart transplantation in children and young adults:early and intermediate-term results[J].Ann Thorac Surg,1995,59(4):804-812.
29 Shaddy RE,Naftel DC,Kirklin JK,et al.Outcome of cardiac transplantation in children.Survival in a contemporary multiinstitutional experience[J].Circulation,1996,94(9 suppl):II69-73.
30 Hosenpud JD,Bennett LE,Keck BM,et al.The registry of the International Society for Heart and Lung Transplantation:Fifteenth official report-1998[J].J Heart Lung Transplant,1998,17(7):656-668.
31 Hsu DT,Quaegebeur JM,Michler RE,et al.Heart transplantation in children with congenital heart disease[J].J Am Coll Cardiol,1995,26(3):743-749.
32 Nai-Hsin Chi,Shu-Chien Huang,Yih-Sharng Chen,et al.Outcome for Pediatric Cardiac Transplantation With and Without Bridge Methods[J].ASAIO J,2007,53(2):241-245.
33 Huang SC,Wu ET,Chen YS,et al.Experience with extracorporeal life support in pediatric patients after cardiac surgery[J].ASAIO J,2005,51(5):517-521.
34 Fenton KN,Webber SA,Danford DA,et al.Long-term survival after pediatric cardiac transplantation and postoperative ECMO support[J].Ann Thorac Surg,2003,76(3):843-847.
35 del Nido PJ,Armitage JM,Fricker FJ,et al.Extracorporeal membrane oxygenation support as a bridge to pediatric heart transplantation[J].Circulation,1994,90(5pt2):1166-1169.
36 Fiser W,Yetman A,Gunselman R,et al.Pediatric arteriovenous extracorporeal membrane oxygenation(ECMO) as a bridge to cardiac transplantation[J].J Heart Lung Transplant,2003,22(7):770-777.
37 Gajarski R,Mosca R,Ohye R,et al.Use of extracorporeal life support as a bridge to pediatric cardiac transplantation[J].J Heart Lung Transplant,2003,22(1):28-34.
38 del Nido Pedro J.Extracorporeal membrane oxygenation for cardiac support in children[J].Ann Thorac Surg,1996,61:336-341.
39 Tenderich G,Koerner MM,Stuettgen B.Mechanical circulatory support after orthotopic heart transplantation[J].Int J Artif Organs,1998,21:414-416.
40 Jae-O Bae,Jason S.Frischer,et al.Extracorporeal membrane oxygenation in pediatric cardiac transplantation[J].J Pedi Surg,2005,40(6):1051-1057.
41 Goldman AP,Cassidy J,de Leval M,et al.The waiting game:bridging to paediatric heart transplantation.Lancet,2003,13;362(9400):1967-1970.
42 The January 2007 Extracorporeal Life Support Organization(ELSO) Extracorporeal Life Support(ECLS) Registry Report International Summary.Ann Arbor,Michigan,Extracorporeal Life Support Organization,2007.
1 Hill JD,De Leval MR,Fallat RJ,et al.Treatment of acute respiratory failure with prolonged extracorporeal oxygenation.Chest,1974,66(0):suppl:38S-40S.
2 Bartlett RH,Gazzaniga AB,Jefferies MR,et al.Extracorporeal membrane oxygenation(ECMO) cardiopulmonary support in infancy.Trans Am Soc Artif Intern Organs,1976,22:80-93.
3 Williams M,Casher J,Joshi N,et al.Insertion of a left ventricular assist device in patients without thorough transplant evaluations:a worthwhile risk?J Thorac Cardiovasc Surg,2003;126(2):436-441.
4 Brown KL,Goldman AP.Neonatal extra-corporeal life support:indications and limitations.Early Hum Dev,2008,84(3):143-148.
5 Schuerer DJ,Kolovos NS,Boyd KV,et al.Extracorporeal membrane oxygenation:current clinical practice,coding,and reimbursement.Chest,2008,134(1):179-184.
6 Mehta U,Laks H,Sadeghi A,et al.Extracorporeal membrane oxygenation for cardiac support in pediatric patients.Am Surg,2000,66(9):879-86.
7 Conrad SA,Rycus PT,Dalton HJ,et al.Extracorporeal Life Support Registry Report 2004.ASAI0 J,2005;51(1):4-10.
8 Doll N,Kiaii B,Borger M,et al.Five-year results of 219 consecutive patients treated with extracorporeal membrane oxygenation for refractory postoperative cardiogenic shock.Ann Thorac Surg,2004,77(1):151-157.
9 Hoskote A,Bohn D,Gruenwald C,et al.Extracorporeal life support after staged palliation of a functional single ventricle:subsequent morbidity and survival.J Thorac Cardiovasc Surg,2006,131(5):1114-1121.
10 Yap HJ,Chen YC,Fang JT,et al.Combination of continuous renal replacement therapies(CRRT)and extraeorporeal membrahe oxygenation(ECMO)for advanced cardiac patients.Ren Fail,2003,25(2):183—193.
11 Golej J,Boigner H,Burda G,et al.Peritoneal dialysis for continuing renal support after cardiac ECMO and hemofiltration.Wien Klin Wochenschr,2002,114(15-16):733-738.
12 O'Neill JM,SchutzeGE,HeulittMJ,etal.Nosocomial infections during extracorporeal membrane oxygenation.Intensive Care Med,2001,27(8):1247-1253.
13 Burket JS,Bartlett RH,Vander Hyde K,et al.Nosocomial in.fections in adult patients undergoing extracorporeal membrane oxygenation.Clin Infect Dis,1999,.28(4):828—833.
14 Pasini E,Aquilani R,Gheorghiade M,et al.Malnutrition,muscle wasting and cachexia in chronic heart failure:the nutritional approach.Ital Heart J,2003,4(4):232-235.
15 Hermans G,Meersseman W,Wilraer A,et al.Extracorporeal membrane oxygenation:experience in an adult medical ICU.Thorac Cardiovasc Surg,2007,55(4):223-228.
16 Nishinaka T,Tatsumi E,Taenaka Y,et al.At least thirty-four days of animal continuous perfusion by a newly developed extracorporeal membrane oxygenation system without systemic anticoagulants.Artif Organs,2002,26(6):548-551.
17 Motomura T,Maeda T,Kawahito S,et al.Development of silicone rubber hollow fiber membrane oxygenator for ECMO.Artif Organs,2003,27(11):1050-1053.
18 Agati S,Ciccarello G,Fachile N,et al.DIDECM0:A new polymethylpentene oxygenator for pediatric extracorporeal membrane oxygenation.ASAIO J,2006,52(5):509-512.
19 Horton S,Thuys C,Bennet M,et al.Experience with the Jostra Rotaflow and Quadrox D oxygenator for ECMO.Perfusion,2004,19(1):17-23.
20 Peek GJ,Killer HM,Reeves R,et al.Early experience with a polymethylpentene oxygenator for adult extracorporeal life support.ASAIO J,2002,48(5):480-482.
21 Toomasian JM,Schreiner RJ,Meyer DE,et al.A polymethylpentene fiber gas exchange for long-term extracorporeal life support.ASAIO J,2005,51(4):390-397.
22 Meyns B,Vercaemst L,Vandezande E,et al.Plasma leakage of oxygenators in ECMO depends on the type of oxygenator and on patient variables.Int J Artif Organs,2005,28(1):30-34.
23 Eash HJ,Jones HM,Hattler BG,et al.Evaluation of plasma resistant hollow fiber membranes for artificial lungs.ASAIO J,2004,50(5):491-497.
24 Cattaneo G,Strauss A,Reul H.et al.Compact intra-and extracorporeal oxygenator developments.Perfusion,2004,19(4):251-255.
25 Levi D,Marelli D,Plunkett M,et al.Use of assist devices and ECMO to bridge pediatric patients with cardiomyopathy to transplantation.J Heart Lung Transplant,2002,21(7):760-770.
1.Brown KL,Goldman AP:Neonatal extra-corporeal life support:indications and limitations.Early Hum Dev 84:143-148,2008.
2.Schuerer DJ,Kolovos NS,Boyd KV,et al:Extracorporeal membrane oxygenation:current clinical practice,coding,and reimbursement.Chest 134:179-184,2008.
3.Shu-Chien Huang,En-Ting Wu,Yih-Shang Chen,et al:Experience with extracorporeal life support in pediatric patients after cardiac surgery.ASAIO J 51:517-521,2005
4.Baslaim G,Bashore J,Al-Malki F,et al:Can the outcome of pediatric extracorporeal membrane oxygenation after cardiac surgery be predicted?Ann Thorac Cardiovasc Surg 12:21-27,2006.
5.Ghez O,Feier H,Ughetto F,et al:Postoperative extracorporeal life support in pediatric cardiac surgery:recent results.ASAIO J51:513-516,2005.
6.Goldman AP,Cassidy J,de Leval M,et al:The waiting game:bridging to paediatric heart transplantation.Lancet 362:1967-1970,2003.
7.Ducan BW,Bhon DJ,Alz AM,et al:Mechanical circulatory support for the treatment of children with acute fulminant myocarditis.J Thorac Cardiovac Surg 122:440-448,2001.
8.Cheung PY,Etches PC,Weardon M,et al:Use of plasma lactate to predict early mortality and adverse outcome after neonatal extracorporeal membrane oxygenation:a prospective cohort in early childhood.Crit Care Med 30:2135-2139,2002.
9.Salman a.Shah,V.Shankar,Kevin B,et al:Clinical outcomes of 84children with congenital heart disease managed with extracorporeal membrane oxygenation after cardiac surgery.ASAIO J 51:504-507,2005.
10.Conrad SA,Rycus PT,Dalton HJ,et al:Extracorporeal Life Support Registry Report 2004.ASAIO J 51:4-10,2005.
11.Doll N,Kiaii B,Borger M,et al:Five-year results of 219 consecutive patients treated with extracorporeal membrane oxygenation for refractory postoperative cardiogenic shock.Ann Thorac Surg 77:151-157,2004.
12.Hoskote A,Bohn D,Gruenwald C,et al:Extracorporeal life support after staged palliation of a functional single ventricle:subsequent morbidity and survival.J Thorac Cardiovasc Surg 131:1114-1121,2006.
13.Meyns B,Vercaemst L,Vandezande E,et al:Plasma leakage of oxygenators in ECMO depends on the type of oxygenator and on patient variables.Int J Artif Organs 28:30-34,2005.
14.Eash HJ,Jones HM,Hattler BG,et al:Evaluation of plasma resistant hollow fiber membranes for artificial lungs.ASAIO J 50:491-497,2004.
15.Cattaneo G,Strauss A,Reul H.et al:Compact intra- and extracorporeal oxygenator developments.Perfusion 19:251-255,2004.
16.Levi D,Marelli D,Plunkett M,et al:Use of assist devices and ECMO to bridge pediatric patients with cardiomyopathy to transplantation.J Heart Lung Transplant 21:760-770,2002.
17.Nishinaka T,Tatsumi E,Taenaka Y,et al:At least thirty-four days of animal continuous perfusion by a newly developed extracorporeal membrane oxygenation system without systemic anticoagulants.Artif Organs 26:548-551,2002.
18.Motomura T,Maeda T,Kawahito S,et al:Development of silicone rubber hollow fiber membrane oxygenator for ECMO.Artif Organs 27:1050-1053,2003.
2.Schuerer DJ,Kolovos NS,Boyd KV,et al.Extracorporeal membrane oxygenation:current clinical practice,coding,and reimbursement[J].Chest,2008,134(1):179-184.
3.Shu-Chien Huang,En-Ting Wu,Yih-Shang Chen,et al.Experience with extracorporeal life support in pediatric patients after cardiac surgery[J].ASAIO J,2005,51(5):517-521.
4.Baslaim G,Bashore J,Al-Malki F,et al.Can the outcome of pediatric extracorporeal membrane oxygenation after cardiac surgery be predicted[J]?Ann Thorac Cardiovasc Surg,2006,12(1):21-27.
5.Ghez O,Feier H,Ughetto F,et al.Postoperative extracorporeal life support in pediatric cardiac surgery:recent results[J].ASAIO J,2005,51(5):513-516.
6.Goldman AP,Cassidy J,de Leval M,et al.The waiting game:bridging to pediatric heart transplantation[J].Lancet,2003,362(9400):1967-1970.
7.Ducan BW,Bhon DJ,Alz AM,et al.Mechamical circulatory support for the treatment of children with acute fulminant myocarditis[J].J Thorac Cardiovac Surg,2001,122(3):440-448.
8.Dietl CA,Wernly JA,Pett SB,et al.Extracorporeal membrane oxygenation support improves survival of patients with severe Hantavirus cardiopulmonary syndrome[J].J Thorac Cardiovasc Surg,2008,135(3):579-584.
9.Shah Salman,Shankar V,Kevin B,et al.Clinical outcomes of 84 children with congenital heart disease managed with extracorporeal membrane oxygenation after cardiac surgery[J].ASAIO J,2005,51(5):504-507.
10.Conrad SA,Rycus PT,Dalton HJ,et al.Extracorporeal Life Support Registry Report 2004[J].ASAIO J,2005,51(1):4-10.
11.Doll N,Kiaii B,Borger M,et al.Five-year results of 219 consecutive patients treated with extracorporeal membrane oxygenation for refractory postoperative cardiogenic shock[J].Ann Thorac Surg,2004,77:151-157.
12.Hoskote A,Bohn D,Gruenwald C,et al.Extracorporeal life support after staged palliation of a functional single ventricle:subsequent morbidity and survival[J].J Thorac Cardiovasc Surg,2006,131(5):1114-1121.
13.Meyns B,Vercaemst L,Vandezande E,et al.Plasma leakage of oxygenators in ECMO depends on the type of oxygenator and on patient variables[J].Int J Artif Organs,2005,28(1):30-34.
14.Eash HJ,Jones HM,Hattler BG,et al.Evaluation of plasma resistant hollow fiber membranes for artificial lungs[J].ASAIO J,2004,50(5):491-497.
15.Cattaneo G,Strauss A,Reul H.et al.Compact intra-and extracorporeal oxygenator developments[J].Perfusion,2004,19(4):251-255.
16.Levi D,Marelli D,Plunkett M,et al.Use of assist devices and ECMO to bridge pediatric patients with cardiomyopathy to transplantation[J].J Heart Lung Transplant,2002,21(7):760-770.
17.Meyns B,Vercaemst L,Vandezande E,et al.Plasma leakage of oxygenators in ECMO depends on the type of oxygenator and on patient variables[J].Int J Artif Organs.2005,28(1):30-34.
18.Agati S,Ciccarello G,Fachile N,et al.DIDECMO:A new polymethylpentene oxygenator for pediatric extracorporeal membrane oxygenation[J].ASAIO J,2006,52(5):509-512.
19.Horton S,Thuys C,Bennet M,et al.Experience with the Jostra Rotaflow and Quadrox D oxygenator for ECMO[J].Perfusion,2004,19(1):17-23.
20.Nishinaka T,Tatsumi E,Taenaka Y,et al.At least thirty-four clays of animal continuous perfusion by a newly developed extracorporeal membrane oxygenation system without systemic anticoagulants[J].Artif Organs,2002,26(6):548-551.
21.Motomura T,Maeda T,Kawahito S,et al.Development of silicone rubber hollow fiber membrane oxygenator for ECMO[J].Artif Organs,2003,27(11):1050-1053.
22.Bakhtiary F,Keller H,Dogan S,et al.Venoarterial extracorporeal membrane oxygenation for treatment of cardiogenic shock:clinical experiences in 45 adult patients[J].J Thorac Cardiovasc Surg,2008,135(2):382-388.
23.Wernovsky G.Current insights regarding neurological and developmental abnormalities in children and young adults with complex congenital cardiac disease[J].Cardiol Young,2006,16(Suppl 1):92-104.
24.Chaturvedi RR,Macrae D,Brown KL,et al.Cardiac ECMO for biventricular hearts after pediatric open heart surgery[J].Heart,2004,90(5):545-551.
25.Mahle WT,Forbess JM,Kirshbom PM,et al.Cost-utility analysis of salvage cardiac extracorporeal membrane oxygenation in children[J].J Thorac Cardiovasc Surg,2005,129(5):1084-1090.
26.Hamrick SE,Gremmels DB,Keet CA,et al.Neurodevelopmental outcome of infants supported with extracorporeal membrane oxygenation after cardiac surgery[J].Pediatrics,2003,111(6 Pt 1):e671-e675.
27.Duncan BW,Ibrahim AE,Hraska V,et al.Use of rapid-deployment extracorporeal membrane oxygenator for the resuscitation of pediatric patients with heart disease after cardiac arrest[J].J Thorac Cardiovasc Surg,1998,116(2):305-311.
28.Morris MC,Wernovsky G,Nadkarni VM.Survival outcomes after extracorporeal cardioplumonary resuscitation instituted during active chest compressions following refractory in-hospital pediatric cardiac arrest[J].Pediatr Crit Care Med,2004,5(5):440-446.
29.Zaritsky A.Extracorporeal cardioplumonary resuscitation:ready for prime time[J]?Pediatr Crit Care Med,2004,5(5):495-496.
1 The January 2007 Extracorporeal Life Support Organization(ELSO) extracorporeal Life Support(ELCS) Registry Report International Summary.Ann Arbor,Michigan,Extracorporeal Life Support Organization,2007.
2 Baffes TG,Fridman JL,Bicoff JP,Whitehill JL:Extracorporeal circulation for support of palliative cardiac surgery in infants[J].Ann Thorac Surg 1970,10(4):354-63.
3 Aharon AS,Drinkwater DC Jr,Churchwell KB,et al.Extracorporeal membrane oxygenation in children after repair of congenital cardiac lesions[J].Ann Thorac Surg,2001,72(6):2095-2101.
4 Duncan BW.Pediatric Cardiac Failure:Management and Use of ECLS.ECMO Extracorporeal Cardiopulmonary Support in Critical Care,3rd edn.Ann Arbor:Extracorporeal Life Support Organization,2005:431-444.
5 Haines NM,Rycus PT,Zwischenberger JB,et al.Extracorporeal Life Support Registry Report 2008:neonatal and pediatric cardiac cases[J].ASAI0 J,2009,55(1):47-52.
6 Thiagarajan RR,Laussen PC.Hospital charges and pediatric ECMO[J].Crit Care Med,2005,33(12):A94-A95.
7 Kolovos NS,Bratton SL,Moler FW,et al.Outcome of pediatric patients treated with extracorporeal life support after cardiac surgery[J].Ann Thorac Surg,2003,76(5):1435-1441.
8 Chaturvedi RR,Macrae D,Brown KL,et al.Cardiac ECMO for biventricular hearts after paediatric open heart surgery[J].Heart,2004,90(5):545-551.
9 Morris MC,Ittenbach RF,Godinez RI et al.Risk factors for mortality in 137 pediatric cardiac intensive care unit patients managed with extracorporeal membrane oxygenation[J].Crit Care Med,2004,32(4):1061-1069.
10 Alsoufi B,Shen I,Karamlou T et al.Extracorporeal life support in neonates,infants,and children after repair of congenital heart disease:modern era results in a single institution[J].Ann Thorac Surg,2005,80(1):15-21.
11 Thourani VH,Kirshbom PM,Kanter KR et al.Venoarterial extracorporeal membrane oxygenation(VA-ECMO) in pediatric cardiac support[J].Ann Thorac Surg,2006,82(1):138-144.
12 Hintz SR,Benitz WE,Colby CE et al.Utilization and outcomes of neonatal cardiac extracorporeal life support:1996-2000[J].Pediatr Crit Care Med,2005,6(1):33-38.
13 Conrad SA,Rycus PT,Dalton H.Extracorporeal Life Support Registry Report 2004[J].ASAI0 J,2005,51(1):4-10.
14 Kocis KC.Pediatric cardiac extracorporeal membrane oxygenation:supporting life or prolonging death[J]?Crit Care Med,2000,28(2):594-595.
15 Fiser SM,Tribble CG,Kaza AK,et al.When to discontinue extracorporeal membrane oxygenation for postcardiotomy support[J].Ann Thorac Surg,2001,71:210-214.
16 Shah SA,Shankar V,Kevin B,etal.Clinical outcomes of 84 children with congenital heart disease managed with extracorporeal membrane oxygenation after cardiac surgery[J].ASAI0 J,2005,51(5):504—507.
17 HetzerR,Stiller B.Technology insight:use of ventricular assist devices in children[J].Nat Clin Pract Cardiovasc Med,2006,3(7):377-386.
18 Charpie JR,Dekeon MK,Goldberg CS,et al.Postoperative hemodynamics after Norwood palliation for hypo plastic left heart syndrome[J].Am J Cardiol,2001,87(2):198—202.
19 Extracorporeal Life Support Organization(ELSO).ELSO Registry report international summary,January 2006.
20 Kulik TJ,Moler FW,Palmisano JM,et al,Outcome-associated factors in pediatric patients treated with extracorporeal membrane oxygenator after cardiac surgery[J].Circulation,1996,94(9 suppl),1163-1168.
21 Ravishankar C,Dominguez TE,Kreutzer J,et al.Extracorporeal membrane oxygenation after stage I reconstruction for hypoplastic left heart syndrome[J].Pediatr Crit Care Med,2006,7(4):319-323.
22 Pizarro C,Davis DA,Healy RM,et al.Is there a role for extracorporeal life support after stage I Norwood[J]?Eur J Cardiothorac Surg,2001,19(3):294-301.
23 Catherine K.Allan MD,Ravi R,et al.Indication for initiation of mechanical circulatory support impacts survival of infants with shunted single-ventricle circulation supported with extracorporeal membrane oxygenation[J].The Journal of Thoracic and Cardiovascular Surgery,2007,133(3):660-667.
24 Huang SC,Wu ET,Chen YS,et al:Experience with extracorporeal life support in pediatric patients after cardiac surgery[J].ASAIO J,2005,51(5):517-521.
25 Baslaim G,Bashore J,Al-Malki F,et al:Can the outcome of pediatric extracorporeal membrane oxygenation after cardiac surgery be predicted[J]?Ann Thorac Cardiovasc Surg,2006,12(1):21-27.
26 Montgomery VL,Strotman JM,Ross MP.Impact of multiple organ system dysfunction and nosocomial infections on survival of children treated with extracorporeal membrane oxygenation after heart surgery[J].Crit Care Med,2000,28(2):526-531.
27 Kanter KR,Pennington G,Weber TR,et al.Extrocorporeal membrane oxygenation for postoperative cardiac support in children[J].J Thorac Cardiovasc Surg,1987,93(1):27-35.
28 Wittenstein B,Ng C,Ravn H,et al.Recombinant factor Ⅶ for severe bleeding during extracorporeal membrane oxygenation following open heart surgery[J].Pediatr Crit Care Med 2005,6:473-76.
29 Meyns B,Vercaemst L,Vandezande E,et al.Plasma leakage of oxygenators in ECMO depends on the type of oxygenator and patient variables[J].Int J Artif Organs,2005,28(1):30-34.
30 Eash HJ,Jones HM,Hattler BG,et al.Evaluation of plasma resistant hollow fiber membranes for artificial lungs[J].ASAIO J,2004,50(5):491-497.
31 Cattaneo G,Strauss A,Reul H,et al.Compact intra-and extracorporeal oxygenator development,;[J].Perfusion,2004,19(4):251-255.
32 Levi D,Marelli D,Plunketu M,et al.Use of assist devices and ECMO to bridge pediatric patients with cardiomyopathy to trans plantation[J].J Heart Lung Transplant,2002,21(7):760-770.
33 Wernovsky G.Current insights regarding neurological and developmental abnormalities in children and young adults with complex congenital cardiac disease[J].Cardiol Young,2006,16(Suppl 1):92-104.
34 Mahle WT,Forbess JM,Kirshbom PM,et al.Cost-utility analysis of salvage cardiac extracorporeal membrane oxygenation in children[J].J Thorac Cardiovasc Surg,2005,129(5):1084-1090.
35 Hamrick SE,Gremmels DB,Keet CA,et al.Neurodevelopmental outcome of infants supported with extracorporeal membrane oxygenation after cardiac surgery[J].Pediatrics,2003,111(6 Pt 1):e671-e675.
1 Taylor IX.Edwards LB.Boucek M M,et al.Registry of the international society for heart and lung transplantation:“twenty—second official adult heart transplant report—2005”[J].J Heart Lung Transplant,2005,24(8):945—982.
2 McMahon AM,van Doom C,Burch M,et al.Improved early outcome for end—stage dilated cardiomyopathy in children[J].J Thorac Cardiovasc Surg,2003,126(6):1781—1787.
3 Undar A,McKenzie ED,MeGarry MC,el al.Outcomes of congenital heart surgery patients after extraeorporeal life support at Texas Childrens Hospital[J].Artif Organs,2004,28(10):963—966.
4 Sachweh JS,TieteAR,Fuchs A,et al.Efficacy of extracorporeal membrane oxygenation in a congenital heart surgery program[J].Clin Res Cardiol,2007,96(4):204—210.
5 Van Doom C,Karimova A,Burch M,et al.Sequential use of extracorporeal membrane oxygenation and the Berlin Heart Left Ventricular Assist Device for 106 day bridge to transplant in a two year—old child[J].ASAI0 J,2005,51(5);668—669.
6 Etz C,Welp H,Rothenburger M,et al.Analysis of platelet function during left ventricular support with the lncor and Exeor system[J].Heart Surg Forum,2004,7(5):E423—427.
7 Hsu RB,Chu SH,Chien CY,et al.HeartMate left ventricular assist device for long term circulatory support[J].J Formos Med ASSOC,2000,99(4):336—340.
8 Goldman AP,Cassidy J,de Leval M,et al.The waiting game:bridging to paediatric heart transplantation[J].Lancet,2003,362(9400):1967—1970.
9 Bartlett RH,Gazzaniga AB,Fong SW,et al.Extracorporeal membrane oxygenator support for cardiopulmonary failure:experience in 28 cases[J].J Thorac Cardiovasc Surg,1977,3(3):375-386.
10 Meliones JN,Custer JR,Snedecor S,et al.Extracorporeal life support for cardiac assist in pediatric patients:review of ELS0 registry data[J].Circulation,1991,84(5 Suppl):III168-172.
11 Dalton HJ,Siewers RD,Fuhrman BP,et al.Extracorporeal membrane oxygenation for cardiac rescue in children with severe myocardial dysfunction[J].Crit Care Med,1993,21(7):1020-1028.
12 Wang SS,Ko wJ,Chen YS,et al.Mechanical bridge with extracorporeal membrane oxygenation and ventricular assist device to heart transplantation[J].Artif Organs,2001,25(8):599—602.
13 Farrar DJ,Hill JD.Recovery of major organ's function in patients awaiting heart transplantation with Thoratec ventricular assist devices[J].J Heart Lunf Transplant,1994,13(6):1123-1132.
14 De Maria R,Minoli L,Parolini M,et al.Prognostic determinants of six-month morbidity and mortality in heart transplant recipients.The Italian Study Group on Infection in Heart Transplantation[J].J Heart Lung Transplant,1996,15(2):124-135.
15 Walley VM,Masters RG,Boone SA,et al.Analysis of deaths after heart transplantation:the University of Ottawa Heart Institute experience[J].J Heart Lung Transplant,1993,12(5):790-801.
16 Bourge RC,Naftel DC,Costanzo-Nordin MR,et al.Pretransplantation risk factors for death after heart transplantation:a multiinstitutional study.The Transplant Cardiologists.Research Database Group[J].J Heart Lung Transplant,1993,12(4):549-562.
17 Ko WJ,Chen YS,Chou NK,et al.Extracorporeal membrane oxygenation rescue after heart transplantation[J].Transplant Proc,2000;32(7):2388-2391.
18 Hoffman TM,Spray TL,Gaynor JW,et al.Survival after acute graft failure in pediatric thoracic organ transplant recipients[J].Pediatr Transplant,2000:4(2):112-117.
19 Kaye MP.The Registry of the International Society for Heart and Lung Transplantation:tenth official report—1993[J].J Heart Lung Transplant,1993,12(4):541—548.
20 Obadia JF,Janier M,Dayoub G,et al.Posttransplant primary heart dysfunction and myocardial stunning[J].J Cardiothorac Vasc Anesth,1997,11(7):880-882.
21 Braunwald E,Kloner RA.The stunned myocardium:prolonged,postischemic ventricular dysfunction[J].Circulation,1982,66(6):1146—1149.
22 Chen JM,Levin HR,Michler RE,et al.Reevaluating the significance of pulmonary hypertension before cardiac transplantation:determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality[J].J Thorac Cardiovasc Surg,1997,114(4):627 -634.
23 Kantrowitz A,Haller JD,Joos H,et al.Transplantation of the heart in an infant and an adult[J].Am J Cardiol,1968,22(6):782-790.
24 Vouhe PR,Tamisier D,Le Bidois J,et al.Pediatric cardiac transplantation for congenital heart defects:surgical considerations and results[J].Ann Thorac Surg,1993,56(6):1239-1247.
25 Heck CF,Shumway SJ,Kaye MP.The registry of the International Society for Heart Transplantation:Sixth official report-1989[J].J Heart Transplant,1989,8(4):271-276.
26 Kanter KR,Tarn VK,Vincent RN,et al.Current results with pediatric heart transplantation[J].Ann Thorac Surg,1999,68(2):527-531.
27 Shaffer KM,Denfield SW,Schowengerdt KO,et al.Cardiac transplantation for pediatric patients with inoperable congenital heart disease[J].Tex Heart Inst J,1998,25(1):57-63.
28 Fullerton DA,Campbell DN,Jones SD,et al.Heart transplantation in children and young adults:early and intermediate-term results[J].Ann Thorac Surg,1995,59(4):804-812.
29 Shaddy RE,Naftel DC,Kirklin JK,et al.Outcome of cardiac transplantation in children.Survival in a contemporary multiinstitutional experience[J].Circulation,1996,94(9 suppl):II69-73.
30 Hosenpud JD,Bennett LE,Keck BM,et al.The registry of the International Society for Heart and Lung Transplantation:Fifteenth official report-1998[J].J Heart Lung Transplant,1998,17(7):656-668.
31 Hsu DT,Quaegebeur JM,Michler RE,et al.Heart transplantation in children with congenital heart disease[J].J Am Coll Cardiol,1995,26(3):743-749.
32 Nai-Hsin Chi,Shu-Chien Huang,Yih-Sharng Chen,et al.Outcome for Pediatric Cardiac Transplantation With and Without Bridge Methods[J].ASAIO J,2007,53(2):241-245.
33 Huang SC,Wu ET,Chen YS,et al.Experience with extracorporeal life support in pediatric patients after cardiac surgery[J].ASAIO J,2005,51(5):517-521.
34 Fenton KN,Webber SA,Danford DA,et al.Long-term survival after pediatric cardiac transplantation and postoperative ECMO support[J].Ann Thorac Surg,2003,76(3):843-847.
35 del Nido PJ,Armitage JM,Fricker FJ,et al.Extracorporeal membrane oxygenation support as a bridge to pediatric heart transplantation[J].Circulation,1994,90(5pt2):1166-1169.
36 Fiser W,Yetman A,Gunselman R,et al.Pediatric arteriovenous extracorporeal membrane oxygenation(ECMO) as a bridge to cardiac transplantation[J].J Heart Lung Transplant,2003,22(7):770-777.
37 Gajarski R,Mosca R,Ohye R,et al.Use of extracorporeal life support as a bridge to pediatric cardiac transplantation[J].J Heart Lung Transplant,2003,22(1):28-34.
38 del Nido Pedro J.Extracorporeal membrane oxygenation for cardiac support in children[J].Ann Thorac Surg,1996,61:336-341.
39 Tenderich G,Koerner MM,Stuettgen B.Mechanical circulatory support after orthotopic heart transplantation[J].Int J Artif Organs,1998,21:414-416.
40 Jae-O Bae,Jason S.Frischer,et al.Extracorporeal membrane oxygenation in pediatric cardiac transplantation[J].J Pedi Surg,2005,40(6):1051-1057.
41 Goldman AP,Cassidy J,de Leval M,et al.The waiting game:bridging to paediatric heart transplantation.Lancet,2003,13;362(9400):1967-1970.
42 The January 2007 Extracorporeal Life Support Organization(ELSO) Extracorporeal Life Support(ECLS) Registry Report International Summary.Ann Arbor,Michigan,Extracorporeal Life Support Organization,2007.
1 Hill JD,De Leval MR,Fallat RJ,et al.Treatment of acute respiratory failure with prolonged extracorporeal oxygenation.Chest,1974,66(0):suppl:38S-40S.
2 Bartlett RH,Gazzaniga AB,Jefferies MR,et al.Extracorporeal membrane oxygenation(ECMO) cardiopulmonary support in infancy.Trans Am Soc Artif Intern Organs,1976,22:80-93.
3 Williams M,Casher J,Joshi N,et al.Insertion of a left ventricular assist device in patients without thorough transplant evaluations:a worthwhile risk?J Thorac Cardiovasc Surg,2003;126(2):436-441.
4 Brown KL,Goldman AP.Neonatal extra-corporeal life support:indications and limitations.Early Hum Dev,2008,84(3):143-148.
5 Schuerer DJ,Kolovos NS,Boyd KV,et al.Extracorporeal membrane oxygenation:current clinical practice,coding,and reimbursement.Chest,2008,134(1):179-184.
6 Mehta U,Laks H,Sadeghi A,et al.Extracorporeal membrane oxygenation for cardiac support in pediatric patients.Am Surg,2000,66(9):879-86.
7 Conrad SA,Rycus PT,Dalton HJ,et al.Extracorporeal Life Support Registry Report 2004.ASAI0 J,2005;51(1):4-10.
8 Doll N,Kiaii B,Borger M,et al.Five-year results of 219 consecutive patients treated with extracorporeal membrane oxygenation for refractory postoperative cardiogenic shock.Ann Thorac Surg,2004,77(1):151-157.
9 Hoskote A,Bohn D,Gruenwald C,et al.Extracorporeal life support after staged palliation of a functional single ventricle:subsequent morbidity and survival.J Thorac Cardiovasc Surg,2006,131(5):1114-1121.
10 Yap HJ,Chen YC,Fang JT,et al.Combination of continuous renal replacement therapies(CRRT)and extraeorporeal membrahe oxygenation(ECMO)for advanced cardiac patients.Ren Fail,2003,25(2):183—193.
11 Golej J,Boigner H,Burda G,et al.Peritoneal dialysis for continuing renal support after cardiac ECMO and hemofiltration.Wien Klin Wochenschr,2002,114(15-16):733-738.
12 O'Neill JM,SchutzeGE,HeulittMJ,etal.Nosocomial infections during extracorporeal membrane oxygenation.Intensive Care Med,2001,27(8):1247-1253.
13 Burket JS,Bartlett RH,Vander Hyde K,et al.Nosocomial in.fections in adult patients undergoing extracorporeal membrane oxygenation.Clin Infect Dis,1999,.28(4):828—833.
14 Pasini E,Aquilani R,Gheorghiade M,et al.Malnutrition,muscle wasting and cachexia in chronic heart failure:the nutritional approach.Ital Heart J,2003,4(4):232-235.
15 Hermans G,Meersseman W,Wilraer A,et al.Extracorporeal membrane oxygenation:experience in an adult medical ICU.Thorac Cardiovasc Surg,2007,55(4):223-228.
16 Nishinaka T,Tatsumi E,Taenaka Y,et al.At least thirty-four days of animal continuous perfusion by a newly developed extracorporeal membrane oxygenation system without systemic anticoagulants.Artif Organs,2002,26(6):548-551.
17 Motomura T,Maeda T,Kawahito S,et al.Development of silicone rubber hollow fiber membrane oxygenator for ECMO.Artif Organs,2003,27(11):1050-1053.
18 Agati S,Ciccarello G,Fachile N,et al.DIDECM0:A new polymethylpentene oxygenator for pediatric extracorporeal membrane oxygenation.ASAIO J,2006,52(5):509-512.
19 Horton S,Thuys C,Bennet M,et al.Experience with the Jostra Rotaflow and Quadrox D oxygenator for ECMO.Perfusion,2004,19(1):17-23.
20 Peek GJ,Killer HM,Reeves R,et al.Early experience with a polymethylpentene oxygenator for adult extracorporeal life support.ASAIO J,2002,48(5):480-482.
21 Toomasian JM,Schreiner RJ,Meyer DE,et al.A polymethylpentene fiber gas exchange for long-term extracorporeal life support.ASAIO J,2005,51(4):390-397.
22 Meyns B,Vercaemst L,Vandezande E,et al.Plasma leakage of oxygenators in ECMO depends on the type of oxygenator and on patient variables.Int J Artif Organs,2005,28(1):30-34.
23 Eash HJ,Jones HM,Hattler BG,et al.Evaluation of plasma resistant hollow fiber membranes for artificial lungs.ASAIO J,2004,50(5):491-497.
24 Cattaneo G,Strauss A,Reul H.et al.Compact intra-and extracorporeal oxygenator developments.Perfusion,2004,19(4):251-255.
25 Levi D,Marelli D,Plunkett M,et al.Use of assist devices and ECMO to bridge pediatric patients with cardiomyopathy to transplantation.J Heart Lung Transplant,2002,21(7):760-770.
1.Brown KL,Goldman AP:Neonatal extra-corporeal life support:indications and limitations.Early Hum Dev 84:143-148,2008.
2.Schuerer DJ,Kolovos NS,Boyd KV,et al:Extracorporeal membrane oxygenation:current clinical practice,coding,and reimbursement.Chest 134:179-184,2008.
3.Shu-Chien Huang,En-Ting Wu,Yih-Shang Chen,et al:Experience with extracorporeal life support in pediatric patients after cardiac surgery.ASAIO J 51:517-521,2005
4.Baslaim G,Bashore J,Al-Malki F,et al:Can the outcome of pediatric extracorporeal membrane oxygenation after cardiac surgery be predicted?Ann Thorac Cardiovasc Surg 12:21-27,2006.
5.Ghez O,Feier H,Ughetto F,et al:Postoperative extracorporeal life support in pediatric cardiac surgery:recent results.ASAIO J51:513-516,2005.
6.Goldman AP,Cassidy J,de Leval M,et al:The waiting game:bridging to paediatric heart transplantation.Lancet 362:1967-1970,2003.
7.Ducan BW,Bhon DJ,Alz AM,et al:Mechanical circulatory support for the treatment of children with acute fulminant myocarditis.J Thorac Cardiovac Surg 122:440-448,2001.
8.Cheung PY,Etches PC,Weardon M,et al:Use of plasma lactate to predict early mortality and adverse outcome after neonatal extracorporeal membrane oxygenation:a prospective cohort in early childhood.Crit Care Med 30:2135-2139,2002.
9.Salman a.Shah,V.Shankar,Kevin B,et al:Clinical outcomes of 84children with congenital heart disease managed with extracorporeal membrane oxygenation after cardiac surgery.ASAIO J 51:504-507,2005.
10.Conrad SA,Rycus PT,Dalton HJ,et al:Extracorporeal Life Support Registry Report 2004.ASAIO J 51:4-10,2005.
11.Doll N,Kiaii B,Borger M,et al:Five-year results of 219 consecutive patients treated with extracorporeal membrane oxygenation for refractory postoperative cardiogenic shock.Ann Thorac Surg 77:151-157,2004.
12.Hoskote A,Bohn D,Gruenwald C,et al:Extracorporeal life support after staged palliation of a functional single ventricle:subsequent morbidity and survival.J Thorac Cardiovasc Surg 131:1114-1121,2006.
13.Meyns B,Vercaemst L,Vandezande E,et al:Plasma leakage of oxygenators in ECMO depends on the type of oxygenator and on patient variables.Int J Artif Organs 28:30-34,2005.
14.Eash HJ,Jones HM,Hattler BG,et al:Evaluation of plasma resistant hollow fiber membranes for artificial lungs.ASAIO J 50:491-497,2004.
15.Cattaneo G,Strauss A,Reul H.et al:Compact intra- and extracorporeal oxygenator developments.Perfusion 19:251-255,2004.
16.Levi D,Marelli D,Plunkett M,et al:Use of assist devices and ECMO to bridge pediatric patients with cardiomyopathy to transplantation.J Heart Lung Transplant 21:760-770,2002.
17.Nishinaka T,Tatsumi E,Taenaka Y,et al:At least thirty-four days of animal continuous perfusion by a newly developed extracorporeal membrane oxygenation system without systemic anticoagulants.Artif Organs 26:548-551,2002.
18.Motomura T,Maeda T,Kawahito S,et al:Development of silicone rubber hollow fiber membrane oxygenator for ECMO.Artif Organs 27:1050-1053,2003.